We appreciate the insightful commentary by Xu et al. on our report of neoadjuvant nivolumab plus ipilimumab in patients with potentially resectable hepatocellular carcinoma (HCC)(1). The three knowledge gaps pointed out by Xu et al. indeed reflect the most critical issues for future research in this rapidly evolving field.
We appreciate the insightful commentary by Xu et al. on our report of neoadjuvant nivolumab plus ipilimumab in patients with potentially resectable hepatocellular carcinoma (HCC)(1). The three knowledge gaps pointed out by Xu et al. indeed reflect the most critical issues for future research in this rapidly evolving field.